FOR IMMEDIATE RELEASE
LUNGevity Foundation awards grants to five outstanding young lung cancer researchers for innovative research into early detection and targeted therapeutics
WASHINGTON (July 24,2012) – LUNGevity Foundation, the nation’s largest lung cancer-focused nonprofit, announced that it has awarded $500,000 in Career Development Awards for Translational Research to fund the research into early detection and targeted therapeutics for lung cancer of five exceptional young scientists. The current and future work of these talented researchers will help ensure continued progress against this cancer that kills more people than the next four cancers combined.
The Foundation supports the largest grant awards program of any lung cancer-focused organization in the United States. In addition to these new awards, LUNGevity and its partners are providing over $2 million of additional funding to support ongoing projects, bringing the two-year funding total to more than $5 million.
2012 Career Development Awards for Translational Research were made to:
LUNGevity’s Career Development Awards for Translational Research program was created with one goal: to identify a cohort of future research leaders who will keep the field of lung cancer research vibrant with new ideas. “LUNGevity’s Career Development Awards give us another vehicle to ensure that researchers at the beginning of their careers have adequate support to continue and grow. We must attract and keep talented scientists in the field of lung cancer research if we are to make progress against this devastating disease, which kills over 160,000 people in this country each year,” said Andrea Stern Ferris, President and Chairman of LUNGevity Foundation.
Awardees will receive $100,000 per year for a possible period of three years and participate in a structured mentoring program at their institutions as well as become ex officio members of LUNGevity’s Scientific Advisory Board for the duration of the award.
Special thanks to Genentech for supporting the LUNGevity Career Development Awards Program.
The $2 million of second-year funding for ongoing projects includes continued support for the following early detection research:
Second-year funding is also continuing to support these targeted therapeutics research projects:
Over 226,000 people will be diagnosed with lung cancer in the U.S. this year, and 84 percent of lung cancer patients die less than five years after their diagnosis, yet government and corporate funding largely overlook lung cancer research. LUNGevity works to make up for this disparity by allocating private donations to translational research that can lead to breakthroughs in diagnosing and treating lung cancer.
The Foundation works with its Scientific Advisory Board, seventeen prominent and leading scientists and researchers, as well as additional experts to ensure that grants are awarded to the proposals with the greatest potential for saving lives. Under the guidance of the Advisory Board, chaired by Dr. Pierre Massion, Associate Professor of Medicine and Cancer Biology in the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt University Medical Center, LUNGevity has become the nation’s premier private grant-making organization funding research for the early detection and effective treatment of lung cancer.
About LUNGevity Foundation
The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients and provide a community for those impacted by lung cancer. It does so by supporting critical research into the early detection and successful treatment of lung cancer, as well as by providing information, resources and a support community to patients and caregivers.
LUNGevity seeks to inspire the nation to commit to ending lung cancer.
For more information about the grants or LUNGevity Foundation, please visit www.lungevity.org.
About Lung Cancer